Shattuck Labs, Inc. ( STTK ) caught my eye because of the massive loss in value over the last five years, and I wanted to see if that was completely warranted and whether tradingMSc in Finance. Long-term horizon investor mostly with 5-10 year horizon. I like to keep investing simple. I believe a portfolio should consist of a mix of growth, value, and dividend-paying stocks but usually end up looking for value more than anything. I also sell options from time to time.Analyst’s Disclosure: I/we have no stock, ...

Core Insights - Shattuck Labs experienced a significant share price increase of 53% over the past week, driven by a positive earnings report and business update [1] Financial Performance - Shattuck Labs reported a fourth quarter and full-year 2025 net loss of $12.6 million ($0.12 per share), an improvement from a loss of $18.7 million in the previous year [2][3] - The company's operational loss decreased to under $13.4 million from $19.6 million in the fourth quarter of 2024, indicating effective cost management [2] Drug Development Progress - The company's lead drug, SL-325, has completed enrollment in all six single-ascending dose cohorts, with full enrollment in the final multiple-ascending dose trial expected by the second quarter of this year [4] - Management anticipates releasing important data from the SL-325 trial during the upcoming quarter, which could influence investor sentiment [4] Financial Position - Shattuck Labs reported over $78 million in cash, equivalents, and short-term investments, which is projected to fund operations into 2029, providing a strong financial runway for drug development [5][6] Market Position - The advancement of SL-325 in its development is viewed positively by investors, positioning Shattuck Labs as a biotech company worth monitoring for potential investment opportunities [6]

Drug Development and Clinical Trials - SL-325 is a high-affinity DR3 blocking monoclonal antibody expected to achieve best-in-class clinical remission rates in patients with inflammatory bowel disease (IBD) due to a more complete blockade of the DR3/TL1A pathway[21]. - The ongoing Phase 1 clinical trial for SL-325 in healthy volunteers is expected to be completed in Q2 2026, with a Phase 2 trial in Crohn's Disease patients anticipated to start in Q3 2026[21][30]. - SL-325 is currently being evaluated in a Phase 1 clinical trial with approximately 72 healthy volunteers, assessing safety, tolerability, and pharmacokinetics[58]. - The company plans to initiate a Phase 2 clinical trial in patients with Crohn's disease in the third quarter of 2026, evaluating two dose levels of SL-325 versus placebo[62]. - The ongoing chronic GLP toxicology study of SL-325 is expected to be completed in the first quarter of 2026, with favorable immunogenicity profiles observed so far[56]. - The approval process for clinical trials varies widely by country, affecting the timeline and potential pricing of products[158]. - The process for obtaining regulatory approvals involves multiple stages, including preclinical tests, IND submission, and clinical trials[86]. - Clinical trials are conducted in three phases, with Phase 3 trials aimed at establishing the overall risk/benefit ratio for product approval[91]. Market Potential and Competition - The IBD market is projected to grow from $23 billion in 2023 to $34 billion by 2030, highlighting the commercial potential for SL-325 and related therapies[38]. - The clinical success of TL1A blocking antibodies has shown placebo-adjusted clinical remission rates of 23-28% in patients with UC, indicating a significant market opportunity for SL-325 if it surpasses these rates[36]. - The company faces competition from clinical-stage therapeutics targeting the TL1A/DR3 axis, including candidates from Teva, Abbvie, and Merck[72]. - Competitors possess greater financial resources and expertise in R&D, manufacturing, and regulatory approvals, which may impact the company's market position[73]. - The company’s commercial opportunity could diminish if competitors develop safer, more effective, or less expensive products[74]. Regulatory Environment - The FDA requires extensive data demonstrating the quality, safety, and efficacy of new therapeutic products before they can be marketed[84]. - The FDA may require additional clinical trials post-approval, known as Phase 4 studies, to gather more information about the product[92]. - A BLA submission must include all relevant data from preclinical and clinical studies, including negative results, and requires a substantial application user fee[94]. - The FDA aims to review standard BLAs within ten months and priority reviews within six months after filing[96]. - The FDA may issue an approval letter or a Complete Response letter after evaluating a BLA, detailing any deficiencies found[99]. - The company must navigate complex regulatory requirements, which require substantial time and financial resources[86]. - The FDA requires manufacturers to perform tests on each lot of biological products before distribution, ensuring compliance with safety, purity, and potency standards[112]. Intellectual Property - The company holds two issued U.S. patents and has four pending international patent applications related to its key technologies as of February 20, 2026[82]. - The patent term for most countries is 20 years from the application filing date, with potential extensions available under U.S. law[80]. - The BPCIA allows for a five-year patent extension post-BLA approval, with a maximum total patent term of 14 years from product licensure[123]. Safety and Efficacy - SL-325's favorable safety profile is supported by non-human primate studies showing no toxicity and durable receptor occupancy for at least two months[22][30]. - SL-325 specifically binds to human DR3 with a 1.3 picomolar affinity and demonstrates a slow off-rate, suggesting durable binding in vivo[46]. - In preclinical studies, SL-325 maintained full DR3 receptor occupancy (RO) at doses of 1 mg/kg or higher within two hours of infusion, lasting throughout a 14-day inter-dose interval[50]. - The No Observed Adverse Effect Level from the GLP toxicology study was determined to be 100 mg/kg, with no infusion-related reactions or organ dysfunction observed[50]. - SL-325 was designed to avoid immune complex formation, which is a common issue with TL1A blocking antibodies, potentially leading to a better immunogenicity profile[43]. Compliance and Legal Considerations - Compliance with healthcare laws, such as the Anti-Kickback Statute and the False Claims Act, is critical to avoid significant penalties and reputational harm[125][127]. - The company faces significant uncertainty regarding the coverage and reimbursement status of any pharmaceutical or biological product for which it obtains regulatory approval[142]. - The company must provide scientific and clinical support for the use of its product candidates to each payor separately, with no assurance of consistent coverage and adequate reimbursement[143]. - The company is subject to evolving regulations regarding the use of artificial intelligence and machine learning, particularly concerning data bias and anti-discrimination[140]. International Regulations - Approval from foreign regulatory authorities is required before commencing clinical trials or marketing products in those countries, similar to the FDA process[157]. - The centralized authorization procedure allows for a single marketing authorization valid across all EU Member States, with a typical evaluation timeframe of 210 days[178]. - The European General Data Protection Regulation (GDPR) imposes strict obligations on the processing of personal data, including health-related data, with potential fines of up to €20 million or 4% of total worldwide annual turnover for noncompliance[165]. - The holder of a MA must adhere to EU pharmacovigilance legislation, ensuring ongoing safety assessment of medicinal products[205].

Financial Performance - Shattuck Labs reported a net loss of $12.6 million for Q4 2025, or $0.12 per share, compared to a net loss of $18.7 million, or $0.37 per share, in Q4 2024[7][8]. - For the full year 2025, the net loss was $48.8 million, or $0.70 per share, down from $75.4 million, or $1.49 per share, in 2024[8]. - The net loss for the year ended December 31, 2025, was $48,809, compared to a net loss of $75,410 in 2024, showing an improvement of 35%[18]. - Basic and diluted net loss per share for the year ended December 31, 2025, was $0.70, compared to $1.49 in 2024, representing a reduction of 53%[18]. - Comprehensive loss for the year ended December 31, 2025, was $48,805, compared to $75,412 in 2024, marking a decrease of 35%[18]. Revenue and Income - Total revenue for the year ended December 31, 2025, was $1,000, compared to $5,721 in 2024, indicating a significant decline[18]. - Interest income for the year ended December 31, 2025, was $2,703, compared to $5,174 in 2024, reflecting a decline of about 48%[18]. - Other income for the year ended December 31, 2025, totaled $2,699, down from $5,157 in 2024, a decrease of approximately 48%[18]. Expenses - Research and Development (R&D) expenses decreased to $9.1 million in Q4 2025 from $15.4 million in Q4 2024, and for the full year, R&D expenses were $35.3 million, down from $67.2 million in 2024[7][8]. - General and Administrative (G&A) expenses for Q4 2025 were $4.3 million, slightly up from $4.2 million in Q4 2024, while full-year G&A expenses decreased to $17.2 million from $19.1 million[7][8]. - Total operating expenses for the year ended December 31, 2025, were $52,508, down from $86,288 in 2024, a decrease of approximately 39%[18]. - Research and development expenses for the three months ended December 31, 2025, were $9,057, down from $15,395 in 2024, reflecting a decrease of approximately 41%[18]. - General and administrative expenses for the three months ended December 31, 2025, were $4,316, slightly up from $4,246 in 2024, showing a marginal increase of 1.6%[18]. Cash Position - Cash and cash equivalents and short-term investments as of December 31, 2025, were approximately $78.1 million, an increase from $73.0 million as of December 31, 2024[9]. - As of February 28, 2026, cash and cash equivalents and short-term investments were approximately $94.5 million, including the recent stock sale proceeds[9]. - Following a common stock sale in Q1 2026, Shattuck expects its cash runway to extend into 2029, assuming full exercise of outstanding warrants[9]. Clinical Development - The Phase 1 clinical trial of SL-325 is nearing completion, with data expected in Q2 2026, and a Phase 2 trial in Crohn's disease anticipated to start in Q3 2026[2][4]. - Shattuck's lead bispecific antibody has entered IND-enabling activities, with target disclosures and preclinical data expected in the first half of 2026[4]. Management Changes - The company appointed Michael Choi, M.D., as Vice President of Clinical Development in November 2025, enhancing its management team[3]. Shareholder Information - The weighted-average shares outstanding for basic and diluted shares increased to 69,584,937 in 2025 from 50,758,290 in 2024, indicating a growth of approximately 37%[18].

Core Viewpoint - Shattuck Labs, Inc. is advancing its lead product candidate, SL-325, a first-in-class DR3 blocking antibody, with ongoing clinical trials and promising financial results, indicating a strong potential for growth in the biotechnology sector focused on inflammatory and immune-mediated diseases [1][2][3]. Financial Results - As of December 31, 2025, Shattuck reported cash and cash equivalents of approximately $78.1 million, an increase from $73.0 million in 2024 [10]. - Research and Development (R&D) expenses for Q4 2025 were $9.1 million, down from $15.4 million in Q4 2024, and total R&D expenses for the year were $35.3 million compared to $67.2 million in 2024 [10]. - General and Administrative (G&A) expenses for Q4 2025 were $4.3 million, slightly up from $4.2 million in Q4 2024, while total G&A expenses for the year decreased to $17.2 million from $19.1 million in 2024 [10]. - The net loss for Q4 2025 was $12.6 million, or $0.12 per share, compared to a net loss of $18.7 million, or $0.37 per share, in Q4 2024 [10]. Clinical Development - SL-325 is currently in a Phase 1 clinical trial, with data expected to be released in Q2 2026, and a Phase 2 trial in Crohn's disease anticipated to start in Q3 2026 [5][6]. - The Phase 1 trial aims to evaluate safety, tolerability, immunogenicity, and pharmacokinetics, with full enrollment expected to be completed in Q2 2026 [6]. - Shattuck is also developing multiple DR3-based bispecific antibodies, with the lead bispecific antibody entering IND-enabling activities [6]. Management Updates - Michael Choi, M.D., was appointed as Vice President of Clinical Development in November 2025, bringing significant experience in inflammatory bowel disease programs [3]. Upcoming Events - Shattuck plans to participate in several investor conferences, including the Leerink Global Healthcare Conference from March 8-11, 2026, where the CEO will present [11].

Summary of Shattuck Labs FY Conference Call Company Overview - **Company**: Shattuck Labs (NasdaqGS:STTK) - **Focus**: Development of DR3 blocking antibodies, specifically targeting the TL1A pathway in inflammatory bowel disease (IBD) [1][2] Core Points and Arguments - **Mechanism of Action**: - DR3 is the receptor for TL1A, and blocking this receptor may provide superior efficacy compared to TL1A blocking antibodies due to its stability and lower immunogenicity [2][4] - TL1A blocking antibodies have a high incidence of anti-drug antibodies (ADA), with over 64% of patients developing ADA, which can lead to reduced efficacy [5][11] - **Clinical Development**: - Shattuck Labs is currently in Phase I clinical trials for their human DR3 blocking antibody, SL-325, and expects to share data in Q2 [6][10] - A Phase 2b randomized controlled study in Crohn's disease is planned to start in Q3, with a target enrollment of 170-180 patients [26][28] - **Efficacy Expectations**: - The company aims for a 100% blockade of TL1A signaling, which is expected to lead to improved clinical outcomes compared to existing therapies [13][18] - Previous studies indicate that ADA levels significantly impact the efficacy of TL1A antibodies, with a 50% drop in efficacy observed as ADA titers increase [18][19] - **Safety Profile**: - The engineered SL-325 antibody is designed to minimize off-target effects and does not cause receptor-mediated endocytosis of DR3, reducing the risk of adverse events [8][9][10] - Non-human primate studies showed no evidence of T cell proliferation or adverse effects, supporting the safety profile expected in humans [25] Additional Important Content - **Competitive Landscape**: - The competitive landscape includes various companies developing TL1A blocking antibodies, while Shattuck Labs is one of the few focusing on DR3 blocking antibodies [6] - **Future Directions**: - Plans to develop bispecific antibodies targeting DR3 are underway, with expectations to share details later this year [34] - The company is considering the potential for life cycle management and indication splitting for SL-425, a half-life extended version of SL-325 [32] - **Market Considerations**: - The company believes that demonstrating efficacy in Crohn's disease will also translate to ulcerative colitis, given the mechanistic similarities and current market dynamics [27] - **Regulatory and Development Strategy**: - The Phase 2b study will assess both high and low doses against a placebo, with a focus on achieving a minimum of 25% improvement in endoscopic response rates [28][29] This summary encapsulates the key points discussed during the conference call, highlighting Shattuck Labs' strategic focus on DR3 blocking antibodies and their anticipated impact on the treatment of inflammatory bowel disease.

Core Insights - Shattuck Labs, Inc. is a clinical-stage biotechnology company focused on developing first-in-class monoclonal and bispecific DR3-blocking antibodies for inflammatory and immune-mediated diseases [4] Group 1: Upcoming Investor Conferences - Shattuck Labs will present at the TD Cowen 46th Annual Health Care Conference on March 2, 2026, at 9:10 AM ET in Boston, MA, with CEO Taylor Schreiber as the presenter [1] - The company will also participate in the Leerink Partners 2026 Global Health Care Conference on March 10-11, 2026, in Miami, FL, featuring one-on-one investor meetings with CEO Taylor Schreiber [2] Group 2: Product Information - SL-325 is a potentially first-in-class DR3 blocking antibody designed for complete and durable blockade of the DR3/TL1A pathway, showing high affinity binding and superior activity compared to TL1A antibodies [3] - SL-325 is currently undergoing evaluation in a Phase 1 clinical trial and has demonstrated a favorable safety profile in non-human primates [3]

Core Insights - Shattuck Labs, Inc. is participating in the Piper Sandler Virtual Novel Targets in Immunology Symposium on February 12-13, 2026, where company management will engage in a fireside chat [1][2] Company Overview - Shattuck Labs, Inc. is a clinical-stage biotechnology company focused on developing novel therapeutics for inflammatory and immune-mediated diseases, with a lead program centered on SL-325, a potential first-in-class antibody targeting the DR3/TL1A pathway [4] - The company has expertise in protein engineering and aims to provide innovative treatments for conditions such as inflammatory bowel disease (IBD) [4] Product Development - SL-325 is a Death Receptor 3 (DR3) blocking antibody designed for complete and durable blockade of the DR3/TL1A pathway, showing high affinity binding and superior activity compared to TL1A antibodies in preclinical studies [3] - SL-325 is currently undergoing evaluation in a Phase 1 clinical trial and has demonstrated a favorable safety profile in non-human primates [3]

Group 1 - Shattuck Labs has shown significant progress in the early development of its investigational drug SL-325, supported by fresh capital [1][9] - The stock price of Shattuck Labs rose by nearly 74% following an upgrade from H.C. Wainwright's analyst Joseph Pantginis, who set a new price target of $6 per share [2][6] - SL-325 is a first-in-class antagonist antibody targeting inflammatory and immune-mediated disorders, currently being evaluated for irritable bowel syndrome (IBS) [4][8] Group 2 - The analyst noted that SL-325 has potential efficacy for multiple indications beyond IBS and expressed optimism about the company's overall pipeline [5] - Shattuck Labs raised approximately $103 million in a private funding round, which is expected to support operations through 2029 [9] - The company reported a reduced net loss of slightly more than $10 million in Q3, down from nearly $17 million in the same period of 2024, indicating improved financial discipline [10]

Core Viewpoint - Shattuck Labs, Inc. has granted inducement equity awards to a newly-hired non-executive officer as part of its strategy to attract talent in the biotechnology sector focused on inflammatory and immune-mediated diseases [1][2]. Group 1: Inducement Equity Awards - The inducement awards consist of non-qualified stock options to purchase 206,000 shares of common stock at an exercise price of $3.23 per share [2]. - The stock options have a maximum term of 10 years, with 25% vesting on November 17, 2026, and the remainder vesting in equal monthly installments over the following 36 months [2]. - These stock options were granted as a material inducement for employment and were approved by the independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4) [2]. Group 2: Company Overview - Shattuck Labs, Inc. is a clinical-stage biotechnology company specializing in developing treatments for inflammatory and immune-mediated diseases [3]. - The company is working on a potentially first-in-class antibody for inflammatory bowel disease (IBD) and other related conditions [3]. - Shattuck's lead program, SL-325, is a DR3 antagonist antibody aimed at achieving a more complete blockade of the DR3/TL1A pathway [3].